Chris Orvig, with colleagues from the BC Cancer Agency (François Bénard, BC Leadership Chair in Functional Cancer Imaging) and TRIUMF (Paul Schaffer, Associate Lab Director, Life Sciences Division and Caterina Ramogida, PhD 2015), has been awarded about $719,000 in the Collaborative Health Research Projects (CHRP) program of CIHR and NSERC for their project "Theranostic Vectors to Treat Cancer with Radiometals” which will combine the expertise of TRIUMF in radionuclide production and radiochemistry with the Orvig group’s knowledge in ligand design for radiometal isotopes and the BCCA mission in cancer diagnosis and therapy.
